We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00033072
First Posted: April 8, 2002
Last Update Posted: January 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Condition Intervention Phase
Amphetamine-Related Disorders Drug: Selegiline Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Single
Primary Purpose: Treatment
Official Title: Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • safety of selegiline
  • pharmacokinetic assessment

Estimated Enrollment: 16
Study Start Date: September 2001
Estimated Study Completion Date: October 2002
Detailed Description:
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
  • Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

  • Please contact site for more information
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00033072


Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
  More Information

ClinicalTrials.gov Identifier: NCT00033072     History of Changes
Obsolete Identifiers: NCT00024882
Other Study ID Numbers: NIDA-CTO-0004-1
First Submitted: April 5, 2002
First Posted: April 8, 2002
Last Update Posted: January 11, 2017
Last Verified: November 2003

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methamphetamine
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors